Digoxin

Digoxin is one of the oldest cardiac drugs still in use — and its dual value is what makes it unique: it strengthens a weak pump AND slows a dangerous rhythm so the heart can fill properly.

Digoxin works through two distinct mechanisms that serve two different clinical goals. First, it inhibits the sodium-potassium ATPase pump on myocardial cells, leading to increased intracellular calcium and stronger contractile force (positive inotrope). This makes it useful in systolic heart failure with reduced ejection fraction (HFrEF), where the heart needs mechanical help. Second, it slows conduction through the AV node via vagal stimulation (negative chronotrope and negative dromotrope), making it a rate-control agent for atrial fibrillation. On the NCLEX, the rate-control indication appears more frequently than the heart failure indication. Digoxin does NOT convert atrial fibrillation to normal sinus rhythm — it only controls ventricular response rate. The therapeutic range is narrow: 0.5–2.0 ng/mL, with heart failure targets often kept at the lower end (0.5–0.9 ng/mL) to reduce toxicity risk. Onset is 1–2 hours oral, 5–30 minutes IV. The long half-life (36–48 hours) means loading doses are used when rapid digitalization is needed.

Key Distinctions

Don't confuse rate control (what digoxin does) with rhythm conversion (what cardioversion or antiarrhythmics do) — digoxin slows the ventricular rate in afib but does not restore sinus rhythm. Students mix up positive inotrope (stronger contraction) with positive chronotrope (faster rate) — digoxin is a positive inotrope but a negative chronotrope. It speeds contraction force while slowing heart rate.

Clinical Pearl

Digoxin makes the heart squeeze harder but beat slower — think 'strong and slow.' Positive inotrope, negative chronotrope, same drug.

Digoxin Toxicity

Digoxin works by inhibiting the sodium-potassium ATPase pump, increasing intracellular calcium to strengthen cardiac contractions (positive inotropic effect) and slowing conduction through the AV node. The therapeutic range is 0.5–2.0 ng/mL, but toxicity can occur even within this range if predisposing factors are present.

The most critical predisposing factor is hypokalemia. Potassium and digoxin compete for the same binding site on the sodium-potassium pump. When potassium is low, more digoxin binds — effectively amplifying the drug's effect without any change in dose. This is why potassium must be checked before administering digoxin.

Renal impairment is the second major risk factor because digoxin is primarily excreted by the kidneys. Declining GFR means the drug accumulates. Elderly patients are at highest risk because they often have both reduced renal function and are more sensitive to cardiac effects.

Key Distinctions

The GI and visual symptoms come first — nausea, vomiting, anorexia, and the classic yellow-green halos around lights. These are easy to dismiss as unrelated complaints. The dangerous cardiac symptoms (bradycardia, heart block, ventricular dysrhythmias) come later.

Don't confuse digoxin's therapeutic bradycardia (expected when the drug is working) with toxic bradycardia. The key differentiator: in toxicity, the bradycardia is accompanied by other symptoms (GI distress, visual changes) and the heart rate is typically below 60 bpm. Always hold digoxin and notify the provider if the apical pulse is below 60.

Clinical Pearl

Before giving digoxin, you need three numbers: the apical heart rate (hold if <60), the serum potassium (hold if <3.5 — hypokalemia potentiates toxicity), and the digoxin level if drawn. The antidote for life-threatening digoxin toxicity is digoxin immune Fab (Digibind). Remember: loop diuretics (furosemide) deplete potassium, creating a dangerous synergy with digoxin — this is one of the most common NCLEX "which finding requires intervention" setups.

Management & Nursing

When digoxin toxicity is confirmed or strongly suspected, the first nursing action is to hold the digoxin and obtain a STAT serum digoxin level and potassium. Correct hypokalemia immediately unless the patient is in high-degree heart block with severe bradycardia — in that scenario, potassium replacement could worsen conduction. The definitive antidote is digoxin immune Fab (Digibind/DigiFab), indicated for life-threatening dysrhythmias (ventricular tachycardia, ventricular fibrillation, symptomatic bradycardia unresponsive to atropine), hemodynamic instability, or serum levels above 10 ng/mL. Digoxin immune Fab binds free digoxin, forming inactive complexes excreted renally. After administration, serum digoxin levels rise dramatically because lab assays measure both bound and free digoxin — this is expected and does not indicate worsening toxicity. Monitor continuous telemetry, potassium closely (digoxin toxicity itself causes hyperkalemia via Na+/K+-ATPase inhibition, and shifts during Fab therapy make potassium unpredictable), and renal function. Atropine may be used for symptomatic bradycardia as a bridge. Avoid electrical cardioversion in digoxin toxicity — it can trigger refractory ventricular fibrillation. If cardioversion is absolutely unavoidable, use the lowest effective energy.

Key Distinctions

Don't confuse a rising digoxin level post-Fab with treatment failure — the lab measures total digoxin, not active drug. Students think cardioversion is always safe for unstable rhythms, but in digoxin toxicity it can cause lethal V-fib. Hypokalemia correction is standard in toxicity, but becomes dangerous when high-degree heart block is present — context changes the intervention.

Clinical Pearl

After Digibind, the digoxin level lies. It goes UP because the lab reads bound drug too. Trust the monitor, not the number.